SBDS siRNA (h): sc-61493



The Power to Question

BACKGROUND

The 249 amino acid Shwachman-Bodian-Diamond syndrome (SBDS) protein belongs to the UPF0023 family. SBDS is widely expressed and may be involved in RNA metabolism. SBDS contains a C-terminal domain, a central domain and an N-terminal domain. The C-terminal domain has a ferredoxin-like fold and is structurally homologous with known RNA-binding domains. The central domain contains a three-helical bundle. The N-terminal domain consists of a three-dimensional α/β fold and is the most frequent target of disease-linked mutations. Mutations in the SBDS gene cause Shwachman-Diamond syndrome (SDS), an autosomal recessive marrow failure disorder marked by hematologic dysfunction, skeletal abnormalities and pancreatic exocrine insufficiency. SDS is also characterized by an increased risk of leukemia and myelodysplasia in as many as one third of affected individuals.

REFERENCES

- Dror, Y., et al. 2005. Shwachman-Diamond syndrome. Pediatr. Blood Cancer 45: 892-901.
- 2. Majeed, F., et al. 2005. Mutation analysis of SBDS in pediatric acute myeloblastic leukemia. Pediatr. Blood Cancer 45: 920-924.
- Kawakami, T., et al. 2005. Genetic analysis of Shwachman-Diamond syndrome: phenotypic heterogeneity in patients carrying identical SBDS mutations. Tohoku J. Exp. Med. 206: 253-259.
- Kuijpers, T.W., et al. 2005. Hematologic abnormalities in Shwachman Diamond syndrome: lack of genotype-phenotype relationship. Blood 106: 356-361.
- Austin, K.M., et al. 2005. The Shwachman-Diamond SBDS protein localizes to the nucleolus. Blood 106: 1253-1258.
- Nicolis, E., et al. 2005. Identification of novel mutations in patients with Shwachman-Diamond syndrome. Hum. Mutat. 25: 410.
- Savchenko, A., et al. 2005. The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism. J. Biol. Chem. 280: 19213-19220.
- 8. Shammas, C., et al. 2005. Structural and mutational analysis of the SBDS protein family. Insight into the leukemia-associated Shwachman-Diamond Syndrome. J. Biol. Chem. 280: 19221-19229.

CHROMOSOMAL LOCATION

Genetic locus: SBDS (human) mapping to 7q11.21.

PRODUCT

SBDS siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SBDS shRNA Plasmid (h): sc-61493-SH and SBDS shRNA (h) Lentiviral Particles: sc-61493-V as alternate gene silencing products.

For independent verification of SBDS (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-61493A, sc-61493B and sc-61493C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20 $^{\circ}$ C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20 $^{\circ}$ C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

SBDS siRNA (h) is recommended for the inhibition of SBDS expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

SBDS (D-9): sc-271350 is recommended as a control antibody for monitoring of SBDS gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor SBDS gene expression knockdown using RT-PCR Primer: SBDS (h)-PR: sc-61493-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**